KLKathryn Elizabeth Lancaster

Kathryn Elizabeth Lancaster

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kathryn Elizabeth Lancaster has a total of 556 co-authors. Here are the top co-authors by number of shared publications:

  • William C. Miller

    Department of Epidemiology, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, Chapel Hill, USA

    12 shared publications
  • Vivian F. Go

    Department of Health Behavior, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, Chapel Hill, USA

    11 shared publications
  • Irving F. Hoffman

    UNC Project, Malawi, Tidziwe Centre, Lilongwe, Malawi

    10 shared publications
  • Angela Marie Parcesepe

    Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, NY, USA

    7 shared publications
  • Mina C. Hosseinipour

    UNC Project, Malawi, Tidziwe Centre, Lilongwe, Malawi

    7 shared publications
  • Thandie Lungu

    University of North Carolina Project-Malawi, Lilongwe, Malawi

    7 shared publications

Latest Publications

  • Open Access

    LAI-PrEP willingness among people who inject drugs in Appalachian Ohio: applying the Information-Motivation-Behavioral Skills Model

    by Madison N. Enderle, Eva Murphy, Jaelyn Murphy, Stacy M. Endres-Dighe, Ucheoma Nwaozuru, David M. Kline, Kathryn E. Lancaster

  • Open Access

    Self-reported and Point-of-Care Biomarkers of Substance Use Measures Among Older Adults with HIV from Low- and Middle-Income Countries

    by Kathryn E. Lancaster, Melissa A. Stockton, Judith A. Hahn, Thida Chanyachukul, Ivan Marbaniang, Dhanushi Rupasinghe, Hai Thi Thanh Nguyen, Edith Kwobah, Helen Byakwaga, Aggrey Semeere, et al.

    Measuring alcohol and other drug (AOD) use remains challenging in HIV care in low- and middle-income countries, where self-report and point-of-care (POC) urine biomarkers capture different time windows. Among 2,059 people with HIV aged 40 years or older across eight IeDEA clinics (2020 to 2022), we examined what self-reported AOD use (AUDIT, ASSIST) and POC urine tests (uEtG for alcohol; 5-panel drug screen) each capture. Self-report identified more use than urine testing (unhealthy alcohol 19.7% versus uEtG-positive 12.2%), consistent with its longer recall window. Higher self-reported alcohol intensity was associated with uEtG positivity in a graded pattern, more strongly among women. Urine-positive but self-report-negative results, more common among men, suggested under-reporting. Self-report and biomarkers answer different measurement questions: self-report for longer-term burden and screening, biomarkers for recent use and corroboration. Combining both, including longer-window biomarkers, can strengthen AOD measurement among older PWH in LMICs.

  • Open Access

    Resilience to Stigma in Medical, Social, and Employment Contexts Among People Who Inject Drugs in Rural Ohio: Adapting the 10-Item Connor-Davidson Resilience Scale

    by Madison N. Enderle, Rebecca H. Neiberg, Stacy M. Endres-Dighe, Nisha Gottfredson O’SHea, Vivian F. Go, William C. Miller, Kathryn E. Lancaster

    People who inject drugs (PWID) experience stigma related to drug use and HIV prevention, which can impede engagement with the HIV prevention continuum. Resilience may buffer against stigma’s harmful effects, but limited research has examined how resilience operates across different social contexts and stigma types among PWID. Using qualitative interviews and cognitive interviews, we adapted the 10-item Connor-Davidson Resilience Scale to measure resilience to drug use-related stigma and HIV prevention-related stigma among PWID in rural Appalachian Ohio in three contexts: medical, social, and employment. To validate the scale adaptations, we administered a quantitative survey. We assessed internal consistency using Cronbach’s alpha and fit Poisson regression models to test the association between high resilience and pre-exposure prophylaxis (PrEP) awareness and overdose response training. Among the 250 PWID who completed the quantitative survey, the six resilience scales demonstrated strong internal consistency. Examining frequency distributions, Bland–Altman plots, and factor analysis, we found the resilience responses varied by stigma type and context. Results of regression models indicated high resilience to HIV prevention-related stigma in the medical context was associated with PrEP awareness (adjusted prevalence ratio [aPR]: 1.37; 95% CI 1.05, 1.80) and overdose response training (aPR: 1.31; 95% CI 1.07, 1.61). Our study provides a novel approach to measuring context-specific resilience to stigma among PWID. Findings highlight the importance of tailoring interventions to both individual resilience and structural stigma, particularly in medical settings. Enhancing resilience and reducing stigma may support greater engagement with HIV prevention and harm reduction services in rural communities.

  • Open Access

    Preferences for clinical trial participation among people who use drugs in rural Oregon and Appalachian Ohio

    by Kathryn E. Lancaster, Caroline W. Koudelka, Miriam R. Elman, Madison N. Enderle, Sarann Bielavitz, Angela T. Estadt, Ryan R. Cook, P. Todd Korthuis, April M. Young


  • Open Access

    Association of fentanyl test strip results and change in drug use behaviors: A multi-state, community-based observational study

    by Kitty H. Gelberg, Nabila El-Bassel, Denise C. Babineau, Rachel A. Vickers-Smith, Laura C. Fanucchi, Janet E. Childerhose, Megan E. Hall, Megan E. Dzurec, Jennifer Villani, Mary R. Russo, et al.


  • Open Access

    Testing a systematically braided alcohol reduction and HIV status neutral intervention among people receiving STI care in Malawi: study protocol for a pilot hybrid type 1 effectiveness-implementation randomized controlled trial

    by Kathryn E. Lancaster, Agatha K. Bula, Mitch M. Matoga, Mina C. Hosseinipour, Irving F. Hoffman, Jaslyn A. Grullon, Eric Umar, Jimmy Msolola, Jessica F. Magidson, Jessica L. Bonumwezi, et al.

    Background: Heavy alcohol use is common in Malawi among people receiving sexually transmitted infections (STI) care and is a critical barrier to the success of HIV prevention and treatment efforts.Methods: This protocol presents a pilot hybrid type 1 effectiveness-implementation trial evaluating the short-term effectiveness and implementation of a scalable evidence-based intervention (EBI) to reduce alcohol use and provide HIV prevention and treatment counseling for people with heavy drinking receiving STI care in Malawi. We developed a 3-session intervention, Treat4All, that uses motivational interviewing, problem-solving skills, psychoeducation, alcohol refusal, HIV prevention and treatment skills building, and goal setting to reduce alcohol and facilitate engagement in HIV prevention and treatment. We have also integrated HIV prevention content to focus on persistent PrEP use and HIV treatment adherence to improve antiretroviral therapy (ART) adherence and viral suppression. We will conduct a two-arm pilot randomized controlled trial (RCT) in an STI care setting in urban Malawi to compare the preliminary effectiveness and implementation of Treat4All to usual care for decreasing the proportion of heavy drinking days, corroborated with phosphatidylethanol, an alcohol biomarker, and improving HIV outcomes (viral suppression among PWH; PrEP use among those at risk). We will randomly assign 160 people receiving STI care in Lilongwe who report heavy drinking (n = 80 people with HIV; PWH; n = 80 people at high risk of HIV acquisition) to Treat4All or usual care.Discussion: Our study will produce a systematically braided, scalable HIV status-neutral EBI for alcohol reduction and optimization of HIV prevention and treatment behaviors to evaluate in a larger effectiveness-implementation trial. Our study will directly expand alcohol reduction and HIV status-neutral programs for alcohol-impacted populations throughout sub-Saharan Africa and other regions where alcohol contributes to the ongoing HIV epidemic.Clinical trial registration: ClinicalTrials.gov, NCT06668363.


  • Open Access

    Characterizing adolescent and youth‐friendly HIV services: a cross‐sectional assessment across 16 global sites

    by Lonnie Embleton, Tavitiya Sudjaritruk, Daisy Maria Machado, Belinda Chihota, Françoise Musabyimana, Julie Jesson, Edith Apondi, Thanyawee Puthanakit, Marco Tulio Luque, Nicola Ellen van Dongen, et al.

    Introduction: Adolescent and youth‐friendly health services (AYFHS) have been promoted as a best practice for adolescents and young people living with HIV (AYLH). However, thorough descriptions of AYFHS for AYLH remain scarce. We sought to characterize adolescent‐friendly HIV services in a global paediatric research consortium.Methods: Cross‐sectional data were collected from 16 global sites in the Adolescent and Young Adult Network of IeDEA (AYANI) of the International epidemiology Databases to Evaluate AIDS consortium between August 2020 and October 2022 using a standardized site assessment tool that collected data on clinic, patient and provider characteristics, differentiated care, and transition to adult services processes. Descriptive analyses characterized the health services available across the participating sites, using frequencies and proportions for categorical variables and medians and interquartile range for continuous variables. Data were analysed using RStudio.Results: Overall, 13 of 16 sites (81%) reported having dedicated adolescent services, which most often consisted of dedicated clinic days (62%, n = 8/13), primarily offered on weekdays. Across all sites, nurses and counsellors delivered services to adolescents. Over half of all clinics (69%, n = 11/16) reported offering health education to adolescents to facilitate adolescent health literacy. Peer educators and navigators were involved in delivering services at 62% of sites, primarily in those with dedicated adolescent services (69%, n = 9/13). There was limited integration of sexual and reproductive health services into HIV clinics for adolescents. With 63% of clinics conducting pregnancy screening, 50% providing family planning methods and 38% providing cervical cancer screening. Under half of all HIV clinics screened for physical abuse or violence (44%, n = 7/16) and sexual abuse or rape (38%, n = 6/16). A low proportion of clinics screened for risk factors related to young key populations, including drug use (56%, n = 9/16), homelessness (38%, n = 6/16) young men having sex with men (31%, n = 5/16) and transactional sex (31%, n = 5/16). Mental health screening for concerns was variable.Conclusions: Findings suggest gaps in AYFHS for AYLH across the HIV clinics included in this analysis. There is a vital need to design health services for AYLH that are accessible, equitable, and effective and meet the global standards for delivering high‐quality healthcare to adolescents.


  • “I'm tired of seeing my friends die”: Barriers and facilitators to participating in clinical trials among rural people who use drugs in the United States

    by Kathryn E. Lancaster, Angela T. Estadt, Madison N. Enderle, Todd P. Korthuis, April M. Young

    Purpose: Participation in clinical trials among people who use drugs (PWUD) in rural areas remains disproportionately low compared to those in urban communities. Our objective was to describe the barriers and facilitators to clinical trial participation among this understudied and underserved population. Methods: We conducted semi‐structured in‐depth interviews among rural PWUD in Kentucky, Ohio, and Oregon. Using the Ickovics and Meisler framework, we classified factors associated with participation in clinical trials among rural PWUD into five categories: the individual, trial and intervention characteristics, participant‐trial staff relationship, clinical trial setting, and features of the disease. We used inductive qualitative analysis methods to identify salient themes. Findings: Thirty‐five rural participants (median age: 39, 51% men) completed in‐depth interviews. Facilitators for rural clinical trial participation were mainly situated within the individual, trial and intervention characteristics, and clinical trial setting. Individual characteristics, such as altruistic motivations to help their communities and peers, as well as trial and intervention characteristics like visit reminders and resource assistance, were the most frequently noted facilitators of clinical trial participation. In contrast, participation barriers were mainly related to participant‐trial staff relationships and disease features. Judgmental and untrustworthy trial staff, along with involvement in the criminal legal system, were obstacles to clinical trial participation. Conclusions: Individual, intrapersonal, and logistical factors described by rural PWUD must be addressed to enhance the participation and retention of this population in clinical trials. Successful clinical trial participation may contribute to equitable access to essential health services by PWUD in rural communities.


  • Open Access

    Prevalence and co‐occurrence of symptoms of mental and substance use disorders among people with HIV age 40 and older in low‐ and middle‐income countries: a cross‐sectional study

    by Angela M. Parcesepe, Melissa Stockton, Charlotte Bernard, Tukiya Kanguya, Edith Kamaru Kwobah, Alvaro Lopez, Gad Murenzi, Jeremy Ross, Albert Minga, Fernanda Maruri, et al.

    Introduction: Due to the increased effectiveness of and access to antiretroviral therapy (ART), people with HIV (PWH) are living longer. As a result, the population of older PWH has increased. Mental and substance use disorders (MSDs) are common and frequently co‐occurring among PWH and are associated with poor HIV care outcomes. Research into the prevalence and co‐occurrence of MSDs among ageing PWH remains limited, particularly in low‐ and middle‐income countries (LMICs).Methods: We analysed data collected between 2020 and 2022 from the International epidemiology Databases to Evaluate AIDS (IeDEA) Sentinel Research Network cohort of PWH aged 40 years or older on ART at 11 HIV clinics in Brazil, Côte d'Ivoire, India, Kenya, Mexico, Uganda, Rwanda, Togo, Vietnam, Zambia and Zimbabwe. We estimated the prevalence and co‐occurrence of unhealthy alcohol use (AUDIT‐C ≥3 for women, ≥4 for men), unhealthy drug use (ASSIST >3 for cannabis, cocaine, amphetamines, inhalants, sedatives, hallucinogens and/or opioids), and moderate to severe symptoms of depression (PHQ‐9 ≥10), anxiety (GAD‐7 ≥10) and post‐traumatic stress disorder (PTSD) (PCL‐5 ≥33). Psychiatric multimorbidity was defined as having symptoms of two or more disorders assessed. Log binomial models assessed the association between socio‐demographic and HIV care characteristics and symptoms of anxiety, depression, PTSD or unhealthy substance use.Results: Of 2821 participants, the prevalence of unhealthy alcohol and drug use was 21% and 5%, respectively. The prevalence of moderate to severe symptoms of depression, anxiety and PTSD was 14%, 9% and 6%, respectively. Overall, the prevalence of psychiatric multimorbidity was 11%. Among those with symptoms of at least one mental health or substance use outcome assessed (n = 1036), the prevalence of psychiatric multimorbidity was 31%. In binomial models, the prevalence of symptoms of depression and anxiety was higher, while the prevalence of unhealthy alcohol and drug use was lower among women than men.Conclusions: Unhealthy alcohol use and symptoms of depression were most commonly reported, among this cohort of PWH aged 40 or older across 11 LMICs. Integration of MSD screening and treatment into HIV care should be prioritized. The effectiveness and implementation of transdiagnostic or multi‐focus mental health treatment approaches in HIV care settings should be examined.


  • Open Access

    Availability of substance use screening and treatment within HIV clinical sites across seven geographic regions within the IeDEA consortium

    by Kathryn E. Lancaster, Melissa Stockton, Molly Remch, C. William Wester, Denis Nash, Ellen Brazier, Adebola Adedimeji, Robert Finlayson, Aimee Freeman, Breanna Hogan, et al.